AZTR Azitra
- 0.710
- -0.038-5.08%
- 0.700
- -0.010-1.41%
Azitra News
Express News | Azitra Shares Are Trading Higher After the Company Received FDA Approval to Proceed With Its Phase 1/2 Clinical Study of ATR-04
Azitra Receives Study May Proceed Letter From The FDA For IND To Treat Skin Rash From EGFR Inhibitors
Express News | Azitra Inc - Preclinical Data Show Atr-04 Reduces Il-36Γ and Staphylococcus Aureus
Express News | Azitra Receives Study May Proceed Letter From the FDA for Ind to Treat Skin Rash From Egfr Inhibitors
Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Trending Stocks Today | Azitra Shoots up 52.75% Post-Market
Azitra Screens First Patient in Phase 1b Trial for Netherton Syndrome
Express News | Azitra Shares Are Trading Higher After the Company Announced That It Screened the First Patient in Its Phase 1b Clinical Trial Evaluating ATR-12 for the Treatment of Netherton Syndrome
Express News | Azitra Screened And Scheduled First Patient To Enroll In Phase 1b Trial Of ATR-12 For Netherton Syndrome
Express News | Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1B Trial of Atr-12 for Netherton Syndrome
Maxim Group Maintains Azitra(AZTR.US) With Buy Rating, Announces Target Price $3
McCarthy's Buy Rating on Azitra Inc: Strong Pipeline and Strategic Financial Positioning
Express News | Azitra Shares Are Trading Higher. The Company Reported Q2 Financial Results
Azitra GAAP EPS of -$2.74, Revenue of $7.5M
Express News | Anitra Q2 2024 GAAP EPS $(2.74) Misses $(0.36) Estimate, Sales $75.000K Down From $172.000K YoY
Express News | Azitra Inc: Completed a Follow-on Offering of $10 Mln in Gross Proceeds Expected to Provide Cash Runway Into 2025
Azitra 2Q Rev $7,500 >AZTR
Express News | Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates
Express News | Azitra Inc - Qtrly Shr Loss $2.74
Azitra | 10-Q: Q2 2024 Earnings Report
Analysis
Price Target
No Data
